---
title: "Medtronic wins FDA breakthrough device tag for Sphere-9 ventricular arrhythmia catheter"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295096557.md"
description: "Medtronic has received FDA Breakthrough Device Designation for its Sphere-9 catheter, intended to treat ventricular arrhythmias. This designation facilitates an expedited US regulatory pathway as the pivotal Sphere VT trial begins patient enrollment."
datetime: "2026-08-06T11:12:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295096557.md)
  - [en](https://longbridge.com/en/news/295096557.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295096557.md)
generator: "portal-rs"
---

# Medtronic wins FDA breakthrough device tag for Sphere-9 ventricular arrhythmia catheter

-   Medtronic received FDA Breakthrough Device Designation for its Sphere-9 catheter to treat ventricular arrhythmias. \* The designation supports an expedited US regulatory pathway as the Sphere VT pivotal trial begins enrolling patients. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MDT.US](https://longbridge.com/en/quote/MDT.US.md)

## Related News & Research

- [MDT Partners with OnTrac AI to Help Credit Unions Build AI Readiness and Take Action](https://longbridge.com/en/news/296794229.md)
- [How Investors Are Reacting To Medtronic (MDT) Cardiac Ablation Surge And Near-Dividend-King Milestone](https://longbridge.com/en/news/296452586.md)
- [Heartflow FFRCT trial data show 44% drop in unnecessary invasive heart catheterizations](https://longbridge.com/en/news/297276738.md)
- [Humacyte says Phase 3 V012 trial shows ATEV extends catheter-free dialysis time in women](https://longbridge.com/en/news/296784335.md)
- [BioCardia: Advancing Regulatory Momentum in Helix Catheter and CardiAMP HF Programs Supports Buy Rating and Unchanged $25 Price Target](https://longbridge.com/en/news/296809944.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**